OSAKA, Japan, January 25, 2022 – Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK)
(“Takeda”) today announced that it has received two WorldStar awards for its bio-PE bottle as primary packaging container1 for solid drugs and its secondary packaging for a pre-filled syringe. The production of the bio-PE bottle derived from plant-based bioethanol reduces CO2 emissions by up to 70 percent and the secondary packaging is fully recyclable due to innovative design. This demonstrates Takeda’s commitment in making environmental sustainability a priority and supports its goal to become net-zero by 2040.
The bio-PE bottles are made from plant-based bioethanol. The bio-PE helps to reduce carbon dioxide (CO2) emissions by up to 70 percent compared to oil-based polyethylene. The bioethanol is used in more than 90% of the raw materials for bio-PE bottles and has acquired the biomass-based plastics mark (BP mark)2 certification.
Takeda was the first company in the pharmaceutical industry to use bio-PE bottles for primary packaging in 2013. At present, bio-PE bottles are used in bulk package for a hypertension treatment product, an acid-related disease agent and other oral formulations. Takeda aims to expand the scope of products packaged in bulk using bio-PE bottles. Green-PE bottles have been tested for critical functionalities such as shelf-life for 36 months, moisture-permeability and shock-resistance, as well as their potential impact on the quality of tablets.
The bio-PE bottle had already received the “Technical Packaging Award” at the Japan Packaging Contest sponsored by the Japan Packaging Institute (JPI) and the “AsiaStar Packaging Award 2021” sponsored by the Asian Packaging Federation (APF).
The packaging is designed for complete recyclability with the paperboard and inner tray following the principles of design for disassembly so it can be easily removed after end of product life. To maintain low environmental impact and minimize packaging weight in comparison to other paperboards (based on a life cycle assessment study), the pack was designed with composite material paperboard and polyethylene terephthalate (PET). It enables it to be easily recycled and its light weight and sleek design make for efficient transport, reducing the space required during the delivery process and helping further reduce carbon emissions.
The secondary packaging was already recognized by the Austrian Green Packaging Star award in 2021.
Takeda is committed to expanding its use of recyclable materials across packaging solutions to help reduce its impact on the environment and advance the industry toward a more sustainable future, which is part of its larger strategy and commitment to net-zero by 2040 throughout its value chain. For example, the company launched its Climate Action Program for the BioLife plasma collection organization, manufacturing and R&D sites in 2020. The program’s long-term goal is to eliminate all greenhouse gas emissions from our operations (scopes 1 and 2) by 2040. Emissions reduction targets were approved by the Science Based Targets initiative (SBTi) and in line with science-based recommendations for limiting global warming.
Learn more about Takeda’s ambitions and progress to reduce our environmental impact here.
Most of our greenhouse gas emissions are scope 3 (supply chain emissions), which means that we have no direct control over them in the course of our business. Nevertheless, together with our suppliers we are working to lower its emissions by 50 percent by 2040. Supply chain improvements, such as the integration of delivery networks, improved loading efficiency and air-to-sea initiatives, have yielded results in the area of domestic and international transportation and storage that contribute to greenhouse gas reduction. Takeda also reports its scope 3 emissions annually and supports its suppliers to set science based targets by 2025. To accelerate the use of renewable electricity Takeda and nine other global pharmaceutical companies brought to life Energize, a program to help suppliers to implement renewable energy solutions.
Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetic and Hematology, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions. For more information, visit https://www.takeda.com.
For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws. The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies.